FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891996081> ?p ?o ?g. }

• W2891996081 abstract "6032 Background: Amcasertib (BBI-503) is an oral first-in-class cancer stemness kinase inhibitor. By targeting multiple serine-threonine stemness kinases, amcasertib inhibits Nanog and other cancer stemness pathways. A phase I clinical trial of amcasertib showed safety and signs of anti-cancer activity in patients (pts) with advanced solid tumors during dose-escalation and RP2D expansion, including pts with advanced head & neck cancer. Methods: Pts with advanced, pre-treated head & neck cancers were enrolled. Amcasertib was administered orally, once or twice daily, in continuous 28-day cycles at a starting dose of 10 mg to 300 mg total daily. Adverse events were categorized according to CTCAE v4.03 and tumor imaging was evaluated per RECIST 1.1 guidelines every 8 weeks. Results: A total of 21 pts were enrolled, 15 with HNSCC and 6 with salivary or parotid gland cancers. Prior treatments included radiation in 90% (19/21), surgery in 71% (15/21) and prior systemic therapy in 90% (19/21, average 3 prior lines, range 1 to 6). Amcasertib was well tolerated with 43% of pts treated at 300 mg daily (n = 9), 33% at 150 mg BID (n = 7), 19% at 200 mg daily (n = 4), and 5% at 10 mg daily (n = 1). Grade 3 AE included diarrhea (n = 4) and nausea (n = 1). Among all patients who received an evaluation per RECIST (n = 16), the objective responses rate (ORR, proportion with partial response [PR] or complete response [CR] per RECIST) was 13% and the disease control rate (DCR, proportion with stable disease [SD] at 8 weeks, PR or CR) was 50%. At 12 months, in the intent-to-treat population (n = 21) 38% of pts were alive. Median overall survival (mOS) of 7.2 months. Conclusions: Clinical safety and encouraging signs of anti-cancer activity were observed in pts with advanced head and neck cancers who have received treatment with amcasertib. Objective response, prolonged disease control, and extended survival have been observed in this pre-treated population with a poor prognosis. Further clinical evaluation of amcasertib in patients with head and neck cancers is warranted. Clinical trial information: NCT01781455." @default.
• W2891996081 created "2018-09-27" @default.
• W2891996081 creator A5000432967 @default.
• W2891996081 creator A5006591586 @default.
• W2891996081 creator A5015961133 @default.
• W2891996081 creator A5033769845 @default.
• W2891996081 creator A5035134011 @default.
• W2891996081 creator A5041365902 @default.
• W2891996081 creator A5044613951 @default.
• W2891996081 creator A5049519373 @default.
• W2891996081 creator A5055961043 @default.
• W2891996081 creator A5059147051 @default.
• W2891996081 creator A5072278925 @default.
• W2891996081 creator A5077884585 @default.
• W2891996081 date "2017-05-20" @default.
• W2891996081 modified "2023-10-02" @default.
• W2891996081 title "A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor in advanced head and neck cancer." @default.
• W2891996081 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.6032" @default.
• W2891996081 hasPublicationYear "2017" @default.
• W2891996081 type Work @default.
• W2891996081 sameAs 2891996081 @default.
• W2891996081 citedByCount "1" @default.
• W2891996081 countsByYear W28919960812019 @default.
• W2891996081 crossrefType "journal-article" @default.
• W2891996081 hasAuthorship W2891996081A5000432967 @default.
• W2891996081 hasAuthorship W2891996081A5006591586 @default.
• W2891996081 hasAuthorship W2891996081A5015961133 @default.
• W2891996081 hasAuthorship W2891996081A5033769845 @default.
• W2891996081 hasAuthorship W2891996081A5035134011 @default.
• W2891996081 hasAuthorship W2891996081A5041365902 @default.
• W2891996081 hasAuthorship W2891996081A5044613951 @default.
• W2891996081 hasAuthorship W2891996081A5049519373 @default.
• W2891996081 hasAuthorship W2891996081A5055961043 @default.
• W2891996081 hasAuthorship W2891996081A5059147051 @default.
• W2891996081 hasAuthorship W2891996081A5072278925 @default.
• W2891996081 hasAuthorship W2891996081A5077884585 @default.
• W2891996081 hasConcept C121608353 @default.
• W2891996081 hasConcept C126322002 @default.
• W2891996081 hasConcept C143998085 @default.
• W2891996081 hasConcept C184235292 @default.
• W2891996081 hasConcept C2776530083 @default.
• W2891996081 hasConcept C502942594 @default.
• W2891996081 hasConcept C54355233 @default.
• W2891996081 hasConcept C71924100 @default.
• W2891996081 hasConcept C86803240 @default.
• W2891996081 hasConceptScore W2891996081C121608353 @default.
• W2891996081 hasConceptScore W2891996081C126322002 @default.
• W2891996081 hasConceptScore W2891996081C143998085 @default.
• W2891996081 hasConceptScore W2891996081C184235292 @default.
• W2891996081 hasConceptScore W2891996081C2776530083 @default.
• W2891996081 hasConceptScore W2891996081C502942594 @default.
• W2891996081 hasConceptScore W2891996081C54355233 @default.
• W2891996081 hasConceptScore W2891996081C71924100 @default.
• W2891996081 hasConceptScore W2891996081C86803240 @default.
• W2891996081 hasLocation W28919960811 @default.
• W2891996081 hasOpenAccess W2891996081 @default.
• W2891996081 hasPrimaryLocation W28919960811 @default.
• W2891996081 hasRelatedWork W2072808966 @default.
• W2891996081 hasRelatedWork W2237148396 @default.
• W2891996081 hasRelatedWork W2546597833 @default.
• W2891996081 hasRelatedWork W2563229662 @default.
• W2891996081 hasRelatedWork W2606319418 @default.
• W2891996081 hasRelatedWork W2741519862 @default.
• W2891996081 hasRelatedWork W2802821385 @default.
• W2891996081 hasRelatedWork W2875685405 @default.
• W2891996081 hasRelatedWork W2889703062 @default.
• W2891996081 hasRelatedWork W2890532168 @default.
• W2891996081 hasRelatedWork W2896101912 @default.
• W2891996081 hasRelatedWork W2901068588 @default.
• W2891996081 hasRelatedWork W2904553013 @default.
• W2891996081 hasRelatedWork W2937710168 @default.
• W2891996081 hasRelatedWork W2945282593 @default.
• W2891996081 hasRelatedWork W2990388375 @default.
• W2891996081 hasRelatedWork W3012143899 @default.
• W2891996081 hasRelatedWork W3200681051 @default.
• W2891996081 hasRelatedWork W3212527083 @default.
• W2891996081 hasRelatedWork W2584093389 @default.
• W2891996081 isParatext "false" @default.
• W2891996081 isRetracted "false" @default.
• W2891996081 magId "2891996081" @default.
• W2891996081 workType "article" @default.